Tag: Neuralink

8 articles

Market Moves

Bill Ackman commits $400 million to a new brain research institute after his daughter's brain haemorrhage

Hedge fund manager Bill Ackman and designer Neri Oxman announced the Ackman Oxman Institute (AOI) on 19-20 August 2026, seeded with $400 million in Pershing Square Inc. stock and a stated further commitment of similar or greater size in a form other than Pershing Square stock. The institute focuses on brain research, rehabilitation, longevity, and human optimization, with Mount Sinai as an important clinical partner. Ackman cited Neuralink, Precision Neuroscience, Synchron, Science Corp and Nudge as examples of the BCI field the institute will engage with, without claiming direct equity in any of them.

Aug 22

Market Moves

The BCI category is broadening beyond motor restoration in 2026

Across the first half of 2026 and the first weeks of the second half, three US Food and Drug Administration Breakthrough Device Designations were granted to non-motor-indication BCI and neuromodulation devices, Cortigent's existing Breakthrough-designated visual cortical prosthesis programme disclosed a secondary stroke motor rehab arm, three first-in-human or investigational-device clinical milestones landed, and two significant peer-reviewed publications extended the field's clinical use case. The motor-restoration pipeline itself continued to expand in the same window. This is a synthesis piece on what the data pattern actually shows and does not show.

Jul 13

Industry News

Neuralink performs its first transdural implant on a Canadian ALS patient

Sgt Lee Marten of the Vancouver Police Department received a Neuralink N1 implant at Toronto Western Hospital on 20 May 2026, becoming the first Canadian ALS patient in the CAN-PRIME trial and the first human anywhere to receive the implant via Neuralink's new transdural surgical technique that preserves the dura rather than cutting it open. The story was broken by CBC News and MobiHealthNews on 2 July 2026.

Jul 4